MannKind At An Inflection Point: Pediatric Expansion Drives The Story
MannKind Corporation has received FDA approval for the pediatric use of its inhaled insulin therapy, Afrezza. This expansion targets children aged 6 and older with type 1 or type 2 diabetes, presenting a significant growth opportunity. The company aims to tap into a concentrated patient base in the U.S., potentially generating substantial revenue.
- ▪MannKind's Afrezza has been approved for pediatric use by the FDA.
- ▪The approval allows the therapy to be used for children aged 6 and older with diabetes.
- ▪This expansion targets a U.S. patient base of approximately 360,000 children.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4911234-mannkind-at-an-inflexion-point-pediatric-expansion-drives-the-story-upgrade"},"author":{"@type":"Person","name":"Petri Dish…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
